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Practice Patterns and Trends in the Use of Medical Therapy in
Patients Undergoing Percutaneous Coronary Intervention in Ontario
Pallav Garg, MBBS, MSc, FRACP; Harindra C. Wijeysundera, MD, PhD, FRCPC; Lingsong Yun, MSc; Warren J. Cantor, MD, FRCPC;
Dennis T. Ko, MD, MSc, FRCPC
Background-—Clinical guidelines emphasize medical therapy as the initial approach to the management of patients with stable
coronary artery disease (CAD). However, the extent to which medical therapy is applied before and after percutaneous coronary
intervention (PCI) in contemporary clinical practice is uncertain. We evaluated medication use for patients with stable CAD
undergoing PCI, and assessed whether the COURAGE study altered medication use in the Canadian healthcare system.
Methods and Results-—A population-based cohort of 23 680 older patients >65 years old) with stable CAD undergoing PCI in
Ontario between 2003 and 2010 was assembled. Optimal medical therapy (OMT) was deﬁned as prescription for a b-blocker,
statin, and either angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in the 90 days before PCI, and the
same medications plus thienopyridine 90 days following PCI. Prior to PCI, 8023 (33.9%) patients were receiving OMT, 11 891
(50.2%) were on suboptimal therapy, and 3766 (15.9%) were not prescribed any medications of interest. There was signiﬁcant
improvement in medical therapy following PCI (OMT: 11 149 [47.1%], suboptimal therapy: 11 591 [48.9%], and none: 940 [4.0%],
P<0.001). Utilization rate of OMT reduced signiﬁcantly after the publication of COURAGE (34.9% before versus 32.8% after,
P<0.001). Similarly, the rate of OMT following PCI was lower in the period after publication of COURAGE (47.3% before versus
46.9% after, P<0.001).
Conclusions-—OMT was prescribed in about 1 in 3 patients prior to PCI and less than half after PCI. In contrast to the anticipated
impact of COURAGE, we found lower rates of medication use in PCI patients after its publication. ( J Am Heart Assoc. 2014;3:
e000882 doi: 10.1161/JAHA.114.000882)
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A dvances in medical therapy have signiﬁcantly improvedthe prognosis of patients with stable coronary artery
disease (CAD).1,2 The Clinical Outcomes Utilizing Revascular-
ization and Aggressive Drug Evaluation (COURAGE) study is a
landmark randomized trial comparing the effectiveness of
optimal medical therapy versus percutaneous coronary inter-
vention (PCI) in patients with stable CAD.3 The study showed
similar rates of cardiovascular events in the overall population
and in the older patient population.3,4 These results are
consistent with prior studies and meta-analyses comparing
medical therapy and PCI for future adverse cardiac events.5–7
In addition, while the degree of angina relief was slightly
higher in the PCI group, substantial improvement in angina
was also seen in the medical therapy group.3 Accordingly,
existing clinical practice guidelines reinforce medical therapy
as the initial approach to the management of patients with
stable angina, and reserve PCI for patients with persistent
symptoms despite optimal medical therapy.8
Despite the widespread attention to the importance of
medical therapy received in the medical literature and in the
lay press, a study demonstrated that there was little change in
medical therapy prior to and after PCI in the United States
after publication of the COURAGE trial.9 There are many
potential reasons why the COURAGE results may not have
changed practice patterns, one of which could be due to the
existing structure of the United States healthcare system,
where substantial ﬁnancial incentives exist to perform
invasive cardiac procedures.10,11 The Canadian healthcare
system, in contrast, has a single-payer model where
incentives to perform procedures are less. As a result, it is
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well known that Canada has lower capacity to perform
coronary invasive procedures in both acute and nonacute
indications as compared to the United States.12–16 We
theorized that physicians in Canada may be more inclined
to translate current knowledge to optimize medical therapy
prior to elective PCI.
We therefore sought to evaluate the practice patterns and
trends in the use of optimal medical therapy in patients with
stable CAD undergoing PCI and whether the publication of
COURAGE changed medical therapy practice patterns in the
Canadian healthcare system.
Methods
The Cardiac Care Network of Ontario maintains a prospective
clinical registry of all individuals who undergo PCI in Ontario,
Canada.17 All hospitals performing PCI are required to collect
information on patients’ clinical characteristics, as well as
procedural information on the number of stents, character-
istics of each stent, and location of stent placement. We
conducted a retrospective cohort study by linking this
registry to several population-based administrative databas-
es, namely, the Discharge Abstract Database of the Canadian
Institute for Health Information (hospital admissions), the
Ontario Health Insurance Plan database (physician service
claims), the Registered Persons Database (vital statistics), the
Ontario Drug Beneﬁt database (prescriptions for individuals
>65 years of age), and the Canadian census.18,19 These
databases have been previously validated for many out-
comes, exposures, and comorbidities. The linkages were
performed using unique encrypted patient identiﬁers to
protect patient conﬁdentiality. The need for patient informed
consent was waived under Ontario’s health information
privacy legislation.
Study Sample
Patients aged 66 years and over with stable CAD undergoing
PCI from December 1, 2003 to March 31, 2010 in Ontario were
included in the study. To deﬁne a cohort of stable CAD patients
for elective procedures, those with myocardial infarction,
revascularization with PCI, or coronary artery bypass grafting
surgery with or without valve surgery within 12 months of the
index PCI were excluded. Patients admitted to the hospital with
acute coronary syndromes were excluded. Patients with severe
comorbidities (eg, metastatic cancer, or severe renal, liver, or
pulmonary disease) within the past year were also excluded
because of competing risk of death and reasons precluding
optimal use of medications. Patients with potential complica-
tions for evidenced-based therapies, such as hyperkalemia or
heart block were also excluded in order to accurately assess
appropriate medication use. Comorbidities were identiﬁed
using the Cardiac Care Network clinical registry, and informa-
tion from the Canadian Institute for Health Information
Discharge Abstract Database, which is based on International
Classiﬁcation of Diseases 10th Revision codes.
Ascertainment of Medical Therapy Before and
After PCI
The Ontario Drug Beneﬁts database was used to ascertain
medication use before and after the index PCI for patients
over 65 years of age. We assessed the use of long-acting
nitrates, b-blockers, calcium channel blockers, statins,
angiotensin-converting enzyme (ACE)-inhibitors, and angio-
tensin receptor blockers (ARB) prior to PCI based on
prescriptions within 90 days prior to and after index PCI. In
addition to those medications, thienopyridine (clopidogrel or
ticlopidine) use was assessed in the 90 days following PCI
(prasugrel and ticagrelor were unavailable during the study
period). There is a very high (>99%) agreement rate between
the Ontario Drug Beneﬁt prescription claims record and
dispensed records from pharmacy.20 Aspirin use could not be
formally evaluated because many patients purchase aspirin
over the counter and this is not recorded in the Ontario Drug
Beneﬁts database.
Deﬁnition of Optimal Medical Therapy
We deﬁned “optimal medical therapy” as prescription for b-
blocker, statin, and either ACE-inhibitor or ARB in the 90 days
prior to PCI, and the same medications along with a
thienopyridine in the 90 days following PCI. ACE-inhibitor or
ARB use was considered in keeping with the COURAGE
deﬁnition of optimal medical therapy where ACE-inhibitors or
ARB were encouraged in all patients with stable CAD for
secondary prevention.3 Suboptimal therapy was deﬁned as
prescription for at least 1 of the above medications. No
medical therapy was deﬁned as the absence of all of these
medications. Recognizing that symptomatic anginal relief is
important in patients with stable angina (particularly pre-PCI),
we considered an alternate deﬁnition of medical therapy
based on the prescription of any 2 medications from the
following in the 90 days pre-PCI: b-blocker, long-acting
nitrate, calcium channel blocker or either ACE-inhibitor or
ARB, and the same medications along with a thienopyridine
and statin in the 90 days following PCI (“symptom-oriented
medical therapy”). Secondary end points also included the
prescription rates of individual medications.
Statistical Analysis
We compared demographic characteristics, clinical charac-
teristics, stratiﬁed by (1) medication use, and (2) COURAGE
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publication using v2 tests for categorical variables and
t tests for continuous variables. We used the period
December 1, 2003 to March 31, 2007 for “pre-COURAGE”
and July 1, 2007 to March 31, 2010 for the “post-COURAGE”
period, allowing for a 3-month period for the dissemination
of the trial results (COURAGE was published on March 26,
2007).
Medication prescription rates before and after PCI were
compared in the overall cohort as well as in the periods
before and after the publication of the COURAGE trial to
examine whether the use of medical therapy changed after
the publication of the COURAGE trial. Continuous variables
are reported as meanSD and compared using t tests
for normally distributed data. Categorical variables are
reported as percentages and compared using the v2 test.
The McNemar test was used to compare medical ther-
apy use before and after the publication of the COURAGE
trial.
We also used a logistic regression model to examine
predictors of optimal medical therapy in the 90 days prior to
the PCI. Variables considered and entered in the regression
model included demographic and clinical variables such as
age, sex, Canadian Cardiovascular Society angina class, prior
cardiovascular disease and other comorbidities, hospital
status, and procedure year. It was possible for some patients
to have been referred for cardiac catheterization by primary
care physicians or other physicians directly, without prior
evaluation by a cardiologist or an internist on an outpatient
basis, and vice versa. Thus, we included outpatient physician
(primary care physician and/or cardiologist or internist) visits
within the preceding 90 days in the model. PCI during the
same session as the cardiac catheterization (commonly
referred to as ad-hoc PCI) was not considered in this model
because it does not impact on medical treatment prior
to PCI.
All statistical tests are 2-sided and a P-value <0.01 was
considered statistically signiﬁcant. All analyses were per-
formed using SAS 9.2 (SAS Institute, Cary, NC).
Results
The initial registry population in the study period included
122 528 PCI procedures. After excluding patients who
were younger than 65 years old (68 591 patients), patients
with myocardial infarction in the past year (19 216
patients), PCI or coronary artery bypass grafting surgery
in the past year (6014 patients), patients with severe
comorbidities or potential contraindications to medical
therapy (1775 patients), and missing data, the ﬁnal study
population included 23 680 patients with stable CAD who
received PCI from December 1, 2003 to March 31, 2010
(Figure).
Baseline Characteristics According to Medical
Therapy Prior to PCI
The mean age of the cohort was 74.1 years and the majority
(64%) were male (Table 1). Of the 23 680 patients under-
going PCI, only 8023 patients (33.9%) were on optimal
medical therapy, 11 891 (50.2%) were receiving suboptimal
medical therapy, and 15.9% were not on any b-blocker,
statin, or either ACE-inhibitor or ARB in the 90 days before
the procedure. In general, patients who were receiving
optimal medical therapy before their PCI had higher rates of
comorbidities, prior cardiovascular disease, and to have
undergone a prior stress test compared to patients who
received suboptimal or no medical therapy prior to PCI, and
were less likely to have moderate to severe angina (Table 1).
In addition, patients on optimal medical therapy were more
often evaluated by a primary care physician and/or cardi-
ologist or an internist in an outpatient setting in the 90 days
prior to PCI. For example, 86.1% of patients receiving
optimal medical therapy were evaluated by a cardiologist or
an internist in the 90 days prior to PCI, compared with
69.6% in the suboptimal medical therapy group, and 27.3%
in the no medical therapy group. Performance of ad-hoc PCI
was common (14 045 patients, 59.3%), and most commonly
observed among patients not on any medical therapy prior
to PCI (85.2%) as compared to those on optimal medical
therapy (46.2%) (Table 1).
Factors Associated With Optimal Medical Therapy
Prior to PCI
In the multivariate analysis, younger age, lower income,
remote history of revascularization, performance of stress
test prior to PCI, and cardiac risk factors or conditions were
associated with signiﬁcantly increased likelihood of being on
optimal medical therapy (Table 2). Cardiologist assessment
was associated with a 2-fold increased likelihood of being on
optimal medical therapy (odds ratio 2.31; 95% CI 2.12 to
2.51). Patients at lower angina classiﬁcation were more likely
to receive optimal therapy than patients with Canadian
Cardiovascular Society class 4 angina. There was no evidence
of increased use of optimal medical therapy over time. In fact,
patients who received PCI in 2003–2005 (odds ratio 1.76;
95% CI 1.58 to 1.96) and 2005–2006 (odds ratio 1.6; 95% CI
1.44 to 1.79) had signiﬁcantly higher likelihood of receiving
optimal medical therapy compared with patients undergoing
PCI in 2009–2010 (Table 2).
Medical Therapy Before and After PCI
Medication prescription rates improved following PCI, with
8023 patients (33.9%, 95% CI, 33.3 to 34.5) receiving optimal
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medical therapy in the 90 days prior and 11 153 patients
(47.1%, 95% CI 46.5 to 47.7) receiving optimal medical
therapy in the 90 days post-PCI (Table 3). Prescription rates
of b-blockers increased signiﬁcantly from 56.9% before PCI to
70.6% after PCI (P<0.001). Similarly, prescription rates of
statins (64.3% to 84.6%), ACE inhibitors or ARBs (62.3% to
74.5%), and clopidogrel (22.7% to 87.1%) increased signiﬁ-
cantly after PCI, whereas the use of long-acting nitrates
(23.5% to 14.5%) and calcium-channel blockers decreased
(38.8% to 30.9%), as might be expected following revascular-
ization (Table 3).
Medical Therapy Before and After COURAGE
A comparable number of patients underwent PCI in the
period before (11 984 patients) and after (11 696 patients)
publication of the COURAGE trial. Although patients were
largely similar in terms of their demographic and clinical
characteristics (Table 4), the rate of optimal medical therapy
prior to PCI reduced slightly following COURAGE (32.8%, 95%
CI 34.1 to 35.8 after versus 34.9%, 95% CI 34.1 to 35.8
before, P<0.001; Table 5). The rates of the individual
medications prescribed before PCI were also lower or
unchanged during the post-COURAGE period. Less than two
thirds of the patients were on symptom-oriented medical
therapy prior to PCI, and rates were lower in the post-
COURAGE period (Table 5).
Similarly, the rate of optimal medical therapy following
PCI was lower in the period after the COURAGE trial
compared with before the trial (47.3%, 95% CI 46.4 to 48.2
before versus 46.9%, 95% CI 46.0 to 47.8 after, P<0.001;
Table 4). Rates of the individual medications prescribed after
PCI were also lower or unchanged during the post-COURAGE
period. Similarly, the rate of symptom-oriented medical
therapy following PCI was unchanged in the post-COURAGE
period (Table 6). There was no signiﬁcant change in
medication prescription rates after the COURAGE trial
publication before or after PCI when stratiﬁed by severity
of angina based on Canadian Cardiovascular Society class
(Table 7).
122,528 PCIs performed (01-Dec-2003 to 31-Mar-2010)
Excluded: 
- Age < 65 years: 68,591
- PCI, CABG in the past year: 6,014
- MI in the past year : 19,216
- Severe comorbidities: 1,775
- Repeat PCI during study period: 750
- CCS class data missing: 542
23,680 patients in the final cohort
1,960 patients without a valid health 
care number
120,568 patients linked with clinical data
Figure. Cohort details. CABG indicates coronary artery bypass graft surgery; CCS,
Canadian Cardiovascular Society; MI, myocardial infarction; PCI, percutaneous coronary
intervention.
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Table 1. Demographic and Clinical Characteristics, Stratiﬁed by Medical Therapy 90 Days Prior to PCI
Characteristics Total (N=23 680)
Optimal (3 Meds)
(N=8023)
Suboptimal (1 or 2 Meds)
(N=11 891) None (N=3766) P-Value
Age, y (at PCI date) 74.15.9 73.75.5 74.45.9 74.46.5 <0.001
66 to 75 14 744 (62.3%) 5219 (65.1%) 7233 (60.8%) 2292 (60.9%) <0.001
76 to 85 7970 (33.7%) 2616 (32.6%) 4123 (34.7%) 1231 (32.7%)
>85 966 (4.1%) 188 (2.3%) 535 (4.5%) 243 (6.5%)
Male 15 148 (64.0%) 5299 (66.0%) 7440 (62.6%) 2409 (64.0%)
Low income 4391 (18.5%) 1594 (19.9%) 2207 (18.6%) 590 (15.7%) <0.001
CCS angina classification
0 1716 (7.2%) 647 (8.1%) 894 (7.5%) 175 (4.6%) <0.001
1 1330 (5.6%) 518 (6.5%) 716 (6.0%) 96 (2.5%)
2 5238 (22.1%) 2313 (28.8%) 2682 (22.6%) 243 (6.5%)
3 5862 (24.8%) 2745 (34.2%) 2868 (24.1%) 249 (6.6%)
4 9534 (40.3%) 1800 (22.4%) 4731 (39.8%) 3003 (79.7%)
Ad-hoc PCI 14 045 (59.3%) 3710 (46.2%) 7128 (59.9%) 3207 (85.2%) <0.001
Prior PCI 2490 (10.5%) 1260 (15.7%) 1111 (9.3%) 119 (3.2%) <0.001
Prior CABG 3144 (13.3%) 1732 (21.6%) 1314 (11.1%) 98 (2.6%) <0.001
Exercise stress test 11 633 (49.1%) 5081 (63.3%) 5954 (50.1%) 598 (15.9%) <0.001
Smoking
Current 8253 (34.9%) 2900 (36.1%) 4104 (34.5%) 1249 (33.2%) 0.004
Ever 10 191 (43.0%) 3566 (44.4%) 5125 (43.1%) 1500 (39.8%) <0.001
Hypertension 15 111 (63.8%) 5755 (71.7%) 7939 (66.8%) 1417 (37.6%) <0.001
Diabetes 7960 (33.6%) 3542 (44.1%) 3830 (32.2%) 588 (15.6%) <0.001
Hyperlipidemia 13 422 (56.7%) 5534 (69.0%) 6863 (57.7%) 1025 (27.2%) <0.001
Cerebrovascular disease 2280 (9.6%) 888 (11.1%) 1195 (10.0%) 197 (5.2%) <0.001
Congestive heart failure 2037 (8.6%) 868 (10.8%) 973 (8.2%) 196 (5.2%) <0.001
Peripheral vascular disease 2163 (9.1%) 917 (11.4%) 1096 (9.2%) 150 (4.0%) <0.001
Pulmonary disease 1101 (4.6%) 305 (3.8%) 628 (5.3%) 168 (4.5%) <0.001
Other medical therapy
Calcium channel blocker 9177 (38.8%) 3497 (43.6%) 5047 (42.4%) 633 (16.8%) <0.001
Long-acting nitrate 5574 (23.5%) 2786 (34.7%) 2659 (22.4%) 129 (3.4%) <0.001
Warfarin 974 (4.1%) 399 (5.0%) 503 (4.2%) 72 (1.9%) <0.001
Teaching hospital 16 126 (68.1%) 5499 (68.5%) 8114 (68.2%) 2513 (66.7%) 0.130
PCI year
2003–2005 3613 (100.0%) 1285 (35.6%) 1820 (50.4%) 508 (14.1%) 0.005
2005–2006 3348 (100.0%) 1165 (34.8%) 1685 (50.3%) 498 (14.9%)
2006–2007 4155 (100.0%) 1444 (34.8%) 2053 (49.4%) 658 (15.8%)
2007–2008 3521 (100.0%) 1190 (33.8%) 1756 (49.9%) 575 (16.3%)
2008–2009 4209 (100.0%) 1382 (32.8%) 2125 (50.5%) 702 (16.7%)
2009–2010 4834 (100.0%) 1557 (32.2%) 2452 (50.7%) 825 (17.1%)
Primary care physician visit* 18 357 (77.5%) 6584 (82.1%) 9527 (80.1%) 2246 (59.6%) <0.001
Cardiologist or internist visit* 16 220 (68.5%) 6910 (86.1%) 8282 (69.6%) 1028 (27.3%) <0.001
CABG indicates coronary artery bypass graft surgery; CCS, Canadian Cardiovascular Society; PCI, percutaneous coronary intervention.
*In the 90 days before PCI.
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Discussion
Our study provides new insights into the practice pattern of
medical therapy in patients with stable angina undergoing
revascularization with PCI in Canada. Our results demonstrate
that only one third of patients undergoing PCI for stable
coronary artery disease were prescribed optimal medical
therapy with b-blockers, statins, and either ACE-inhibitors or
ARBs in the 90 days prior to their procedure. While medica-
tion prescription rates improved following PCI, less than half
of patients were receiving optimal medical therapy in the
90 days following PCI. In addition, there was no substantial
change in this practice pattern over the study period,
including following the publication and dissemination of the
COURAGE trial in 2007. These ﬁndings suggest that despite
mounting evidence of the importance of medical therapy in
patients with stable coronary disease, and the strong clinical
guideline recommendations for maximizing the medical ther-
apy prior to and in conjunction with revascularization,8 most
patients are still treated with inadequate medical therapy. We
also found relatively low rates of use of anti-anginals such as
nitrates prior to PCI even in patients with signiﬁcant
symptoms.
The concept of applying optimal medical therapy was
endorsed in the COURAGE trial, in which 90% of the
medically treated cohort was compliant with aspirin, statin,
and b-blocker therapies at 1 year.3 At 3 years, 75% of
patients were on ACE inhibitors or ARBs, 92% were on a
statin, and 86% were on a b-blocker in the medical therapy
arm and similar compliance was present even in the PCI
group. This is in contrast to “real world” practice, both in
terms of prescription and compliance with recommended anti-
anginal and preventative medical therapy. Our results are in
keeping with prior large studies that have shown much lower
rates of medical therapy in patients with coronary artery
disease.9,21–23 Borden et al showed that among patients with
stable CAD undergoing PCI in the United States, less than half
received optimal medical therapy prior to PCI and approxi-
mately two thirds of patients received it after discharge from
the hospital following PCI, with little change after the
publication of the COURAGE trial.9
We initially hypothesized that physicians may be more
inclined to apply COURAGE results in the Canadian healthcare
system, where there is a government-regulated single-payer
model with perhaps less incentive to perform procedures and
where waiting lists are traditionally longer.10,15 In addition,
under the Ontario Drug Beneﬁt Program, medications are
generally available with low co-payment and dispensing fees.
This was expected to result in better medication prescription
and adherence compared with other jurisdictions with limited
medication coverage and higher co-payments. However, we
found that the prescription rates of optimal medical therapy
were lower in our study compared with the US study. In
addition, a surprising 16% of the patients undergoing PCI had
not received any cardiac medications we assessed prior to the
PCI procedure.
We also found that patients with angina at higher Canadian
Cardiovascular Society class were less likely to be on medical
therapy prior to PCI. The reasons for this ﬁnding are not
entirely clear, although it is possible that these patients had
Table 2. Factors Associated With Optimal Medical Therapy
Prior to PCI*
Variables Odds Ratio (95% CI) P-Value
Age, y (reference >85 years) <0.001
66 to 75 1.37 (1.15 to 1.64)
76 to 85 1.31 (1.1 to 1.57)
Male 1.07 (1.0 to 1.14) 0.042
Low income 1.15 (1.06 to 1.24) <0.001
CCS angina classification
(reference CCS 4)
<0.001
0 to 1 1.6 (1.44 to 1.78)
2 1.89 (1.72 to 2.08)
3 2.03 (1.86 to 2.23)
Prior PCI 1.79 (1.63 to 1.97) <0.001
Prior CABG 2.04 (1.89 to 2.22) <0.001
Exercise stress test 1.35 (1.26 to 1.45) <0.001
Current smoking 1.0 (0.93 to 1.06) 0.930
Hypertension 1.46 (1.36 to 1.57) <0.001
Diabetes 1.62 (1.52 to 1.72) <0.001
Hyperlipidemia 1.64 (1.53 to 1.77) <0.001
Cerebrovascular disease 1.1 (1.0 to 1.22) 0.055
Congestive heart failure 1.57 (1.41 to 1.74) <0.001
Peripheral vascular disease 1.15 (1.04 to 1.27) 0.007
Pulmonary disease 0.63 (0.55 to 0.73) <0.001
Teaching hospital 0.98 (0.92 to 1.05) 0.620
PCI year
(2009–2010 as reference)
<0.001
2003–2005 1.76 (1.58 to 1.96)
2005–2006 1.6 (1.44 to 1.79)
2006–2007 1.2 (1.06 to 1.29)
2007–2008 1.15 (1.04 to 1.28)
2008–2009 1.06 (1.05 to 1.21)
Primary care physician visit 1.13 (1.05 to 1.21) 0.002
Cardiologist or internist visit 2.2 (2.02 to 2.41) <0.001
CABG indicates coronary artery bypass graft surgery; CCS, Canadian Cardiovascular
Society; PCI, percutaneous coronary intervention.
*The model predicts the use of optimal medical therapy 90 days prior to PCI.
The adjusted odds ratios were derived from multivariate logistic regression model.
This model had a c-index (area under the receiving operating curve) of 0.74.
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more symptoms given the lack of appropriate medical therapy
prior to PCI. An alternative explanation may be that physicians
want to refer these patients for more urgent catheterization
and PCI, given the severity of their symptoms even before
instituting appropriate medical therapy, although there is little
justiﬁcation for such an approach.
There are several possible reasons why medical therapy is
underprescribed in patients with stable CAD and why the
COURAGE trial results have not been implemented in common
clinical practice. First, it has been shown that patients
overestimate the beneﬁts of PCI by believing that PCI would
prevent myocardial infarction or fatality.24 Such belief may
lead to a desire of a “quick-ﬁx” for their symptoms rather than
to comply with a daily medication regimen for a long period of
time. Second, physicians may not universally accept the
results of recent trials, such as COURAGE, or there may be a
knowledge gap regarding appropriate management of patients
with stable CAD, believing that PCI is better compared to
medical therapy.25 For example, a recent study indicates that
about 20% of cardiologists still believe that the PCI may
reduce death or prevent myocardial infarction in stable CAD
patients.24 Third, we found that many patients who were on
suboptimal or no therapy received PCI as an ad-hoc proce-
dure. The reasons for such high rates of ad-hoc PCI are likely
multifactorial. From the patient’s perspective, combining the
diagnostic angiogram and the intervention in a single setting
is convenient, and this approach forms part of both patients’
and physicians’ expectations. It is also possible that physi-
cians and patients may be more inclined to undertake ad-hoc
PCI rather than prescribe medical therapy and delay any
revascularization, given the severity of their patients’ symp-
toms. Nevertheless, while ad-hoc PCI may be more acceptable
in the acute coronary syndrome setting where PCI improves
outcomes, delayed or non–ad-hoc PCI may be preferable in
patients with stable angina.26 This allows for a proper and
frank discussion of all therapeutic options in a more relaxed
setting, including optimization or intensiﬁcation of medical
therapy.
Our study adds to the growing literature indicating
suboptimal use of proven therapies in practice and has
important implications for the contemporary management of
patients with stable CAD. Current practice guidelines recom-
mend optimizing medical therapy for improvement of
symptoms and prognosis prior to consideration of revascu-
larization. Improved utilization of medications is a signiﬁcant
opportunity for improvement in health care of patients with
cardiovascular disease. Revascularization may be safely
deferred or may not be required in patients appropriately
treated with medical therapy, thereby reducing societal costs
at the same time as improving survival. Our study reinforces
the importance of appropriateness criteria for coronary
revascularization. Indeed, policy makers and insurers may
eventually mandate the need for appropriate and aggressive
medical therapy before reimbursing PCI procedures.
Our study has several important limitations. First, we did
not assess prescription of aspirin because we were unable to
capture this medication in the Ontario Drug Beneﬁts
database because many patients purchase aspirin over the
counter rather than through the drug beneﬁt program.
Second, our study was limited to an older cohort >65 years
Table 3. Medication Prescription Rates Before and After PCI
Medication
No. (%), (95% CI) of Patients
P-ValuePre-PCI (90 Days) Post-PCI (90 Days)
Optimal medical therapy 33.9 (33.3 to 34.5) 47.1 (46.5 to 47.7) <0.001
Suboptimal medical therapy 50.2 (49.6 to 50.9) 48.9 (48.3 to 49.6) 0.001
None 15.9 (15.4 to 16.4) 4.0 (3.7 to 4.2) <0.001
Individual medications
Long-acting nitrate 23.5 (23.0 to 24.1) 14.5 (14.0 to 14.9) <0.001
b-Blocker 56.9 (56.2 to 57.5) 70.6 (70.1 to 71.2) <0.001
Calcium channel blocker 38.8 (38.1 to 39.4) 30.9 (30.3 to 31.5) <0.001
Statin 64.3 (63.6 to 64.9) 84.6 (84.1 to 85.0) <0.001
ACE-I/ARB 62.3 (61.7 to 63.0) 74.5 (73.9 to 75.0) <0.001
Clopidogrel 22.7 (22.1 to 23.2) 87.1 (86.7 to 87.5) <0.001
Symptom-oriented medical therapy 61.2 (60.6 to 61.8) 57.9 (57.3 to 58.5) <0.001
Optimal medical therapy is deﬁned as prescription for b-blocker, statin, and either ACE inhibitor or ARB in the 90 days prior to PCI, and the same medications along with a thienopyridine in
the 90 days following PCI. Suboptimal therapy is deﬁned as prescription of at least 1 of the above individual medications. Symptom-oriented medical therapy is deﬁned as prescription of
any 2 medications from the following in the 90 days pre-PCI: b-blocker, long-acting nitrate, calcium channel blocker or either ACE inhibitor or ARB, and the same medications along with a
thienopyridine and statin in the 90 days following PCI. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; PCI, percutaneous coronary intervention.
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of age) because we did not have information on prescriptions
for younger patients. However, the elderly population
represents a high-risk group with higher baseline cardiovas-
cular risk proﬁle and derives equal if not more beneﬁt from
medical therapy as younger patients. Third, medication
prescription was used as a surrogate for medication use
and compliance, and we were unable to determine whether
patients actually took their medication once it was dis-
pensed. However, this misclassiﬁcation bias would tend to
overestimate medication use. Fourth, we were unable to
control for all factors that might inﬂuence a physician’s
decision to prescribe (or not prescribe) medications, or fully
deﬁne contraindications to therapy with these medications,
which could underestimate optimal medical therapy use.
Table 4. Demographic and Clinical Characteristics Before and After Publication of COURAGE
Characteristics Total (N=23 680) Pre-COURAGE (N=11 984) Post-COURAGE (N=11 696) P-Value
Age, y (at PCI date) 74.15.9 73.85.6 74.46.1 <0.001
Age group, y
66 to 75 14 744 (62.3%) 7714 (64.4%) 7030 (60.1%) <0.001
76 to 85 7970 (33.7%) 3910 (32.6%) 4060 (34.7%)
>85 966 (4.1%) 360 (3.0%) 606 (5.2%)
Male 15 148 (64.0%) 7692 (64.2%) 7456 (63.7%) 0.483
Low income 4391 (18.5%) 2300 (19.2%) 2091 (17.9%) 0.009
CCS angina classification
0 1716 (7.2%) 913 (7.6%) 803 (6.9%) <0.001
1 1330 (5.6%) 685 (5.7%) 645 (5.5%)
2 5238 (22.1%) 2625 (21.9%) 2613 (22.3%)
3 5862 (24.8%) 3386 (28.3%) 2476 (21.2%)
4 9534 (40.3%) 4375 (36.5%) 5159 (44.1%)
Ad-hoc PCI 14 045 (59.3%) 6495 (54.2%) 7550 (64.6%) <0.001
Prior PCI 2490 (10.5%) 922 (7.7%) 1568 (13.4%) <0.001
Prior CABG 3144 (13.3%) 1537 (12.8%) 1607 (13.7%) 0.038
Exercise stress test 11 633 (49.1%) 6214 (51.9%) 5419 (46.3%) <0.001
Smoking
Current 8253 (34.9%) 5107 (42.6%) 3146 (26.9%) <0.001
Ever 10 191 (43.0%) 5107 (42.6%) 5084 (43.5%) 0.185
Hypertension 15 111 (63.8%) 6548 (54.6%) 8563 (73.2%) <0.001
Diabetes 7960 (33.6%) 3800 (31.7%) 4160 (35.6%) <0.001
Hyperlipidemia 13 422 (56.7%) 5472 (45.7%) 7950 (68.0%) <0.001
Cerebrovascular Disease 2280 (9.6%) 1183 (9.9%) 1097 (9.4%) 0.199
Congestive heart failure 2037 (8.6%) 977 (8.2%) 1060 (9.1%) 0.012
Peripheral vascular disease 2163 (9.1%) 1133 (9.5%) 1030 (8.8%) 0.084
Pulmonary disease 1101 (4.6%) 490 (4.1%) 611 (5.2%) <0.001
Other medical therapy
Calcium channel blocker 9177 (38.8%) 4688 (39.1%) 4489 (38.4%) 0.244
Long-acting nitrate 5574 (23.5%) 3209 (26.8%) 2365 (20.2%) <0.001
Warfarin 974 (4.1%) 359 (3.0%) 615 (5.3%) <0.001
Teaching hospital 16 126 (68.1%) 8404 (70.1%) 7722 (66.0%) <0.001
Primary care physician visit 18 357 (77.5%) 9458 (78.9%) 8899 (76.1%) <0.001
Cardiologist or internist visit 16 220 (68.5%) 8343 (69.6%) 7877 (67.3%) <0.001
CABG indicates coronary artery bypass graft surgery; CCS, Canadian Cardiovascular Society; COURAGE, Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation;
PCI, percutaneous coronary intervention.
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While it is possible that we have not captured all contrain-
dications to therapy, this is unlikely to be different in the
period before or after the COURAGE trial, thus not altering
the ﬁnding that optimal medical therapy use did not differ
after COURAGE. Finally, our data are from Ontario and may
not reﬂect prescribing practices from other areas. However,
Ontario is the largest province and encompasses a third of
the Canadian population.
In conclusion, we found that among patients with stable
CAD undergoing PCI, only a third of patients were prescribed
Table 5. Medication Prescription Rates Before and After Publication of COURAGE in the 90 Days Prior to PCI
Medication Total
No. (%), (95% CI) of patients
P-Value*Pre-COURAGE Post-COURAGE
Pre-PCI
Optimal medical therapy 8023 (33.9%) 34.9 (34.1 to 35.8) 32.8 (31.9 to 33.6) <0.001
Suboptimal medical therapy 11 891 (50.2%) 50.0 (49.1 to 50.9) 50.4 (49.5 to 51.3) 0.519
None 3766 (15.9%) 15.0 (14.4 to 15.7) 16.8 (16.1 to 17.5) <0.001
Individual medications
Long-acting nitrate 5574 (23.5%) 26.8 (26.0 to 27.6) 20.2 (19.5 to 21.0) <0.001
b-Blocker 13 467 (56.9%) 59.3 (58.4 to 60.2) 54.4 (53.5 to 55.3) <0.001
Calcium channel blocker 9177 (38.8%) 39.1 (38.3 to 40.0) 38.4 (37.5 to 39.3) 0.244
Statin 15 215 (64.3%) 64.3 (63.5 to 65.2) 64.2 (63.3 to 65.0) 0.787
ACE-I/ARB 14 762 (62.3%) 62.7 (61.9 to 63.6) 61.9 (61.1 to 62.8) 0.205
Clopidogrel 5366 (22.7%) 23.6 (22.8 to 24.3) 21.7 (21.0 to 22.5) <0.001
Symptom-oriented medical therapy 61.2 (60.6, 61.8) 63.6 (62.8 to 64.5) 58.7 (57.8 to 59.6) <0.001
Optimal medical therapy is deﬁned as prescription for b-blocker, statin, and either ACE inhibitor or ARB in the 90 days prior to PCI. Suboptimal therapy is deﬁned as prescription of at least
1 of the above individual medications. Symptom-oriented medical therapy is deﬁned as the prescription of any 2 medications from the following in the 90 days pre-PCI: b-blocker, long-
acting nitrate, calcium channel blocker or either ACE inhibitor or ARB. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; COURAGE, Clinical Outcomes
Utilizing Revascularization and Aggressive Drug Evaluation; PCI, percutaneous coronary intervention.
*McNemar test.
Table 6. Medication Prescription Rates Before and After Publication of COURAGE in the 90 Days After PCI
Medication Total
No. (%), (95% CI) of patients
P-Value*Pre-COURAGE Post-COURAGE
Post-PCI
Optimal medical therapy 11 149 (47.1%) 47.3 (46.4 to 48.2) 46.9 (46.0 to 47.8) 0.520
Suboptimal medical therapy 11 591 (48.9%) 49.1 (48.2 to 50.0) 48.8 (47.9 to 49.7) 0.567
None 940 (4.0%) 3.6 (3.3 to 3.9) 4.4 (4.0 to 4.7) 0.002
Individual medications
Long-acting nitrate 3426 (14.5%) 15.9 (15.2 to 16.5) 13.0 (12.4 to 13.7) <0.001
b-Blocker 16 729 (70.6%) 71.3 (70.5 to 72.1) 70.0 (69.1 to 70.8) 0.023
Calcium channel blocker 7320 (30.9%) 31.4 (30.5 to 32.2) 30.4 (29.6 to 31.3) 0.125
Statin 20 028 (84.6%) 84.1 (83.4 to 84.8) 85.1 (84.4 to 85.7) 0.038
ACE-I/ARB 17 638 (74.5%) 75.9 (75.1 to 76.6) 73.1 (72.3 to 73.9) <0.001
Clopidogrel 20 629 (87.1%) 86.7 (86.1 to 87.3) 87.5 (86.9 to 88.1) 0.053
Symptom-oriented medical therapy 57.9 (57.3, 58.5) 58.2 (57.3 to 59.1) 57.6 (56.7 to 58.5) 0.316
Optimal medical therapy is deﬁned as prescription for b-blocker, statin, and either ACE inhibitor or ARB along with a thienopyridine in the 90 days following PCI. Suboptimal therapy
is deﬁned as prescription of at least 1 of the above individual medications. Symptom-oriented medical therapy is deﬁned as the prescription of any 2 medications from the following:
b-blocker, long-acting nitrate, calcium channel blocker or either ACE inhibitor or ARB, along with a thienopyridine and statin in the 90 days following PCI. ACE-I indicates angiotensin-
converting enzyme inhibitor; ARB, angiotensin receptor blocker; COURAGE, Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation; PCI, percutaneous coronary
intervention.
*McNemar test.
DOI: 10.1161/JAHA.114.000882 Journal of the American Heart Association 9
Medical Therapy in PCI for Stable CAD Garg et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
Table 7. Medication Prescription Rates Before and After Publication of COURAGE, Stratiﬁed by Before and After PCI and
CCS Class
Medication
No. (%), (95% CI) of Patients
P-Value*Pre-COURAGE Post-COURAGE
CCS class 0 to 2 (N=8284)
Pre-PCI
Optimal medical therapy 1775 (42.0%) 1703 (41.9%) 0.929
Suboptimal medical therapy 2151 (50.9%) 2141 (52.7%) 0.104
None 297 (7.0%) 217 (5.3%) 0.001
Nitrate 1042 (24.7%) 875 (21.5%) <0.001
b-Blocker 2857 (67.7%) 2726 (67.1%) 0.609
Calcium channel blocker 1629 (38.6%) 1659 (40.9%) 0.034
Statin 3165 (74.9%) 3209 (79.0%) <0.001
ACE-I/ARB 2957 (70.0%) 2848 (70.1%) 0.914
Clopidogrel 1339 (31.7%) 1347 (33.2%) 0.155
Post-PCI
Optimal medical therapy 1728 (40.9%) 1560 (38.4%) 0.020
Suboptimal medical therapy 2440 (57.8%) 2455 (60.5%) 0.013
None 55 (1.3%) 46 (1.1%) 0.482
Nitrate 532 (12.6%) 487 (12.0%) 0.402
b-Blocker 2823 (66.8%) 2583 (63.6%) 0.002
Calcium channel blocker 1400 (33.2%) 1484 (36.5%) 0.001
Statin 3515 (83.2%) 3469 (85.4%) 0.006
ACE-I/ARB 3132 (74.2%) 2863 (70.5%) <0.001
Clopidogrel 3750 (88.8%) 3677 (90.5%) 0.009
CCS Class 3 to 4 (N=15 396)
Pre-PCI
Optimal medical therapy 2413 (31.1%) 2132 (27.9%) <0.001
Suboptimal medical therapy 3842 (49.5%) 3757 (49.2%) 0.713
None 1506 (19.4%) 1746 (22.9%) <0.001
Nitrate 2167 (27.9%) 1490 (19.5%) <0.001
b-Blocker 4249 (54.7%) 3635 (47.6%) <0.001
Calcium channel blocker 3059 (39.4%) 2830 (37.1%) 0.003
Statin 4545 (58.6%) 4296 (56.3%) 0.004
ACE-I/ARB 4561 (58.8%) 4396 (57.6%) 0.134
Clopidogrel 1486 (19.1%) 1194 (15.6%) <0.001
Post-PCI
Optimal medical therapy 3939 (50.8%) 3922 (51.4%) 0.445
Suboptimal medical therapy 3448 (44.4%) 3248 (42.5%) 0.018
None 374 (4.8%) 465 (6.1%) <0.001
Nitrate 1369 (17.6%) 1038 (13.6%) <0.001
b-Blocker 5723 (73.7%) 5600 (73.3%) 0.579
Calcium channel blocker 2359 (30.4%) 2077 (27.2%) <0.001
Statin 6563 (84.6%) 6481 (84.9%) 0.579
Continued
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optimal medical therapy in the 90 days prior to their
procedure, and less than half were receiving optimal medical
therapy in the 90 days following PCI. There was no substantial
change in medical therapy prescription practice pattern over
the study period, including following the publication of the
COURAGE trial.
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